uracil and c-peptide
uracil has been researched along with c-peptide in 2 studies
Research
Studies (2)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Christopher, R; Covington, P; Davenport, M; Fleck, P; Karim, A; Mekki, QA; Wann, ER | 1 |
| Hu, P; Li, H; Liu, D; Liu, H; Liu, X; Liu, Y; Xiao, X; Yang, J | 1 |
Trials
2 trial(s) available for uracil and c-peptide
| Article | Year |
|---|---|
Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: a randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes.
Topics: Adult; Aged; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Female; Fructosamine; Glycated Hemoglobin; Humans; Insulin; Male; Middle Aged; Piperidines; Placebos; Time Factors; Treatment Outcome; Uracil | 2008 |
Dipeptidyl-Peptidase-IV Inhibitors, Imigliptin and Alogliptin, Improve Beta-Cell Function in Type 2 Diabetes.
Topics: Adolescent; Adult; Aged; Blood Glucose; C-Peptide; China; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Female; Glycated Hemoglobin; Humans; Imidazoles; Insulin; Insulin-Secreting Cells; Male; Middle Aged; Piperidines; Pyridines; Treatment Outcome; Uracil; Young Adult | 2021 |